Literature DB >> 2898423

Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome.

P Ruszniewski1, F Girard, R Benamouzig, M Mignon, S Bonfils.   

Abstract

Cushing's syndrome, caused by ectopic ACTH production during Zollinger-Ellison syndrome, raises difficult therapeutic problems. We report a case of clinical and biological efficacy of long acting somatostatin (SMS) in this condition. In a short term study with 200 micrograms SMS bid, symptoms of hypercorticism disappeared while cortisol and ACTH serum concentrations fell below the normal values. Longterm treatment was instituted with 50 micrograms SMS bid. Excellent clinical efficacy as well as normal cortisol and ACTH serum concentrations were maintained during the nine month follow up. Lipotrophic hormone (LPH) serum concentration remained raised. No decrease in size of hepatic metastases was observed. Long acting somatostatin analogues may be useful in endocrine paraneoplastic syndromes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898423      PMCID: PMC1433734          DOI: 10.1136/gut.29.6.838

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas.

Authors:  E C Ellison; T M O'Dorisio; J Sparks; H S Mekhjian; J J Fromkes; E A Woltering; L C Carey
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

2.  Preparation and evaluation of ACTH antibodies.

Authors:  M F Proeschel; J C Courvalin; M Donnadieu; M Binoux; F Girard
Journal:  Acta Endocrinol (Copenh)       Date:  1974-03

3.  [Determination of plasma cortisol by competitive binding with transcortin].

Authors:  M T Pham-Huu-Trung
Journal:  Ann Biol Clin (Paris)       Date:  1970       Impact factor: 0.459

4.  Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995.

Authors:  J J Shepherd; G B Senator
Journal:  Lancet       Date:  1986-09-06       Impact factor: 79.321

5.  Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.

Authors:  G Boden; I G Ryan; B L Eisenschmid; J J Shelmet; O E Owen
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

6.  Current approach to the management of tumoral process in patients with gastrinoma.

Authors:  M Mignon; P Ruszniewski; S Haffar; D Rigaud; E Rene; S Bonfils
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

7.  Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

Authors:  S W Lamberts; P Uitterlinden; L Verschoor; K J van Dongen; E del Pozo
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

8.  Multiple mechanisms of somatostatin inhibition of adrenocorticotropin release from mouse anterior pituitary tumor cells.

Authors:  T Reisine
Journal:  Endocrinology       Date:  1985-06       Impact factor: 4.736

9.  Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue.

Authors:  J L Ch'ng; J V Anderson; S J Williams; D H Carr; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-12

10.  Cushing's syndrome in patients with the Zollinger-Ellison syndrome.

Authors:  P N Maton; J D Gardner; R T Jensen
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

View more
  7 in total

1.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 2.  Treatment of Zollinger-Ellison syndrome.

Authors:  Paola Tomassetti; Davide Campana; Lydia Piscitelli; Elena Mazzotta; Emilio Brocchi; Raffaele Pezzilli; Roberto Corinaldesi
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

Review 3.  Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.

Authors:  Paola Tomassetti; Teresa Salomone; Marina Migliori; Davide Campana; Roberto Corinaldesi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Authors:  B Ambrosi; D Bochicchio; C Fadin; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

Review 5.  The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

Authors:  Valentina Guarnotta; Chiara Martini; Maria Vittoria Davì; Genoveffa Pizza; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2017-10-10       Impact factor: 3.633

6.  Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.

Authors:  Lynsey M Daniels; Marian Khalili; William F Morano; Michaela Simoncini; Beth C Mapow; Andrea Leaf; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2019-12-09       Impact factor: 2.754

7.  Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature.

Authors:  Da Zhang; Lin Lu; Hui-Juan Zhu; Yu Xiao; Xian-Lin Han; Shun-Da Du; Hua-Dan Xue; Qing-Xing Liu; Zhao-Hui Zhu; Ming-Ming Hu; Xiao Zhai; Xiao-Ping Xing; Zhao-Lin Lu
Journal:  Int J Endocrinol       Date:  2022-02-28       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.